Sadhna Verma, MD, MBA, FSAR

Sadhna M. Verma, MD, MBA, FSAR

University of Cincinnati

Cincinnati, Ohio

Sadhna Verma, MD, MBA, FSAR, is an Adjunct Professor-Affiliate of Radiology at the University of Cincinnati in Ohio. Dr. Verma established and continues to serve as the Director of the Prostate MRI Program at the University of Cincinnati and established the university’s CT imaging program for CT Urography and CT Enterography. Dr. Verma is the associate Chair of Quality and Performance Improvement at the Prostate Cancer Midwest Center of Excellence and the Director of the Prostate Cancer Imaging Program for the U.S. Department of Veterans Affairs. She is an international expert in the fields of GI and GU Imaging.

Dr. Verma earned her medical degree from the University of Louisville in Kentucky. She then completed an internship in Internal Medicine at the University of Pittsburgh in Pennsylvania. Dr. Verma completed a residency in Diagnostic Radiology and a fellowship in Health Service and Outcomes Research at the University of Cincinnati and then completed a fellowship in Body Imaging/3D Imaging at Johns Hopkins University in Baltimore, Maryland. Dr. Verma earned her MBA from the University of Chicago Booth School of Business in Illinois.

Dr. Verma is a member of the International Prostate MRI Working Group. She conducts local and national workshops to help train radiologists and inform clinicians and patients about this test. Dr. Verma has over 100 published articles and book chapters in her field.

Talks by Sadhna M. Verma, MD, MBA, FSAR

Post Ablation Imaging: Interpretation and Standardized Reporting

Sadhna M. Verma, MD, MBA, FSAR | Feb 2026

Dr. Sadhna Verma describes expected post-ablation MRI changes and explains structured reporting systems that support accurate assessment.

Panel Discussion: MRI and PSMA Discordance

Abhinav Sidana, MD, MPH, FACS, Steven P. Rowe, MD, PhD, Mark Emberton, MD, FRCS, Arvin K. George, MD and Sadhna M. Verma, MD, MBA, FSAR | Feb 2026

Experts discuss MRI and PSMA discordance, demonstrating how combined imaging enhances lesion evaluation.

Prostate MRI Update — What’s New on the Horizon?

Sadhna M. Verma, MD, MBA, FSAR | Feb 2026

Dr. Sadhna Verma presents a 2025 update on prostate MRI covering PI-RADS v2.1, reconstruction advances, MRI-supported screening, and focal therapy planning.

PIRADS V2.1 – What a Urologist Needs to Know?

Sadhna M. Verma, MD, MBA, FSAR | Jan 2025

Sadhna Verma, MD, MBA, FSAR, begins this 20-minute presentation by emphasizing the exponential growth of prostate MRI usage and its critical role in prostate cancer detection. Before diving into PI-RADS, the multiparametric MRI approach is explained. T2-weighted sequences are highlighted as the best for anatomical visualization.

PI-RADS scoring, a standardized Likert-like system ranging from 1 to 5, assesses the likelihood of malignancy of a lesion based on size, location, and imaging characteristics. PI-RADS version 2.1 introduces refinements, particularly for transition zone lesions. The updated guidelines also incorporate templates to standardize reporting and emphasize quality assurance. Central zone tumors are recognized for their aggressive nature and specific imaging features.

Dr.Verma shares images to illustrate the scoring refinements of PI-RADS version 2.1. Despite advancements, quality variability in imaging and interpretation remains a concern. Collaborative initiatives led by the American College of Radiology aim to enhance diagnostic accuracy. Dr. Verma emphasizes the need for ongoing quality assurance and training to address current limitations and improve clinical outcomes.

Interpretation of Post Focal Therapy Imaging Target and Pifab

Sadhna M. Verma, MD, MBA, FSAR | Dec 2024

Sadhna Verma, MD, MBA, FSAR, explores advancements in imaging and reporting for post-focal therapy in prostate cancer, highlighting the emergence of two scoring systems, TARGET and PI-FAB. This 16-minute presentation provides an overview of expected multiparametric MRI findings at different post-treatment intervals, describing immediate changes like coagulative necrosis and late findings such as fibrosis and scarring.

Dr. Verma introduces TARGET, a consensus-based system focusing on MRI timing, technical parameters, and interpretation. The PI-FAB system, developed from expert opinion, similarly prioritizes dynamic contrast imaging. Comparative examples illustrate their application.

Preliminary studies reveal moderate inter-reader agreement for both systems, though sensitivity and specificity vary, underscoring the importance of experience in interpretation. Despite promising results, the presenter stresses the need for validation through large, multicenter cohorts and integration with molecular imaging to enhance diagnostic accuracy.